Profil
Natalie Berner is currently an Independent Director at BioInvent International AB since 2022, Managing Director at Redmile Group LLC since 2018, Director at Sensorion SA, Non-Executive Director at Redx Pharma Plc since 2021, and Director at Hansa Biopharma AB starting in 2025.
Formerly, Ms. Berner was a Research Associate at New York University School of Medicine.
Education includes an undergraduate degree from Brown University conferred in 2012.
Postes actifs de Natalie Berner
| Sociétés | Poste | Début |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Directeur/Membre du Conseil | 12/07/2022 |
| REDX PHARMA LTD | Directeur/Membre du Conseil | 18/05/2021 |
| SENSORION | Directeur/Membre du Conseil | - |
| HANSA BIOPHARMA AB | Directeur/Membre du Conseil | 02/09/2025 |
Redmile Group LLC
Redmile Group LLC Investment ManagersFinance Redmile focuses primarily on making investments in US and non-US healthcare companies. They may also invest in fields related to healthcare where due diligence shows those healthcare assets are the driving force behind value creation and in other sectors from time to time. The firm uses fundamental research as part of their investment process. Their protocols include company financial models, market models, investment theses, and regular dialogue. Redmile’s sources include contacts with physicians, focus outside US, dialogue with companies, attendance at medical conferences; meetings with private companies, and regular dialogue within the team. | Gestionnaire de Portefeuille-Actions | 01/08/2018 |
Anciens postes connus de Natalie Berner
| Sociétés | Poste | Fin |
|---|---|---|
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formation de Natalie Berner
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Brown University
Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioInvent International AB
BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
Redmile Group LLC
Redmile Group LLC Investment ManagersFinance Redmile focuses primarily on making investments in US and non-US healthcare companies. They may also invest in fields related to healthcare where due diligence shows those healthcare assets are the driving force behind value creation and in other sectors from time to time. The firm uses fundamental research as part of their investment process. Their protocols include company financial models, market models, investment theses, and regular dialogue. Redmile’s sources include contacts with physicians, focus outside US, dialogue with companies, attendance at medical conferences; meetings with private companies, and regular dialogue within the team. | Finance |
Hansa Biopharma AB
Hansa Biopharma AB Pharmaceuticals: MajorHealth Technology Develops therapies and medicines for the treatment of immunomodulatory | Health Technology |
Sensorion SA
Sensorion SA Pharmaceuticals: MajorHealth Technology Operates as a research and development company that discovers drugs to treat inner ear disorders | Health Technology |
Redx Pharma Plc
Redx Pharma Plc Pharmaceuticals: MajorHealth Technology Discovers and develops novel, small molecule & targeted therapeutics for treatment of cancer and fibrotic disease | Health Technology |
New York University School of Medicine
New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















